William Hrushesky to Anemia
This is a "connection" page, showing publications William Hrushesky has written about Anemia.
Connection Strength
0.957
-
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
Score: 0.168
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.160
-
End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
Score: 0.156
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
Score: 0.129
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.117
-
Erythropoietin usage in patients with cancer. Cancer J Sci Am. 1995 Nov-Dec; 1(4):243-6.
Score: 0.116
-
Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995 Apr; 95(4):1650-9.
Score: 0.111